These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 2475379)
1. Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Digestion; 1989; 42(2):61-9. PubMed ID: 2475379 [TBL] [Abstract][Full Text] [Related]
2. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557 [TBL] [Abstract][Full Text] [Related]
3. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini]. Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851 [TBL] [Abstract][Full Text] [Related]
4. CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini. Iwamoto Y; Yamamoto R; Kuzuya T Pancreas; 1987; 2(1):85-90. PubMed ID: 2437574 [TBL] [Abstract][Full Text] [Related]
5. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas. Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini. Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413 [TBL] [Abstract][Full Text] [Related]
7. [Inhibitory effect of CR 1409 (cholecystokinin antagonist) on pancreatic exocrine secretion in rats]. Shiratori K; Watanabe S; Shimizu K; Moriyoshi Y; Chang JH; Takeuchi T Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):70-6. PubMed ID: 2471850 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. Iwamoto Y; Nakamura R; Akanuma Y Gastroenterol Jpn; 1984 Feb; 19(1):53-8. PubMed ID: 6202584 [TBL] [Abstract][Full Text] [Related]
9. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies. Louie DS; Liang JP; Owyang C Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681 [TBL] [Abstract][Full Text] [Related]
10. Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini. Akiyama T; Tachibana I; Otsuki M Int J Pancreatol; 1993 Oct; 14(2):167-73. PubMed ID: 7506744 [TBL] [Abstract][Full Text] [Related]
11. The effect of CR 1409, a potent CCK receptor antagonist, on basal and stimulated pancreatic secretion in rat. Takács T; Nagy I; Pap A; Varró V Pancreas; 1990; 5(1):60-4. PubMed ID: 2293712 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini. Akiyama T; Otsuki M Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754 [TBL] [Abstract][Full Text] [Related]
13. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues. Niederau C; Niederau M; Williams JA; Grendell JH Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321 [TBL] [Abstract][Full Text] [Related]
14. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. Scarpignato C; Varga G; Dobronyi I; Papp M Br J Pharmacol; 1989 Mar; 96(3):661-9. PubMed ID: 2470456 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of CR-1409, a competitive inhibitor of cholecystokinin, on pancreatic exocrine secretion in the conscious rat. Miyasaka K; Nakamura R; Funakoshi A; Kitani K Tohoku J Exp Med; 1988 Jun; 155(2):165-72. PubMed ID: 3212779 [TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of CR-1409 on amylase secretion and intracellular Ca2+ mobilization in rat pancreatic acini in vitro. Shinozaki H; Funakoshi A; Wakasugi H; Abe M Jpn J Physiol; 1989; 39(4):585-93. PubMed ID: 2481056 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754 [TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas. Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728 [TBL] [Abstract][Full Text] [Related]
19. Proglumide analogues: potent cholecystokinin receptor antagonists. Jensen RT; Murphy RB; Trampota M; Schneider LH; Jones SW; Howard JM; Gardner JD Am J Physiol; 1985 Aug; 249(2 Pt 1):G214-20. PubMed ID: 2411147 [TBL] [Abstract][Full Text] [Related]
20. The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats. Takács T; Nagy I; Pap A; Varró V Pancreas; 1988; 3(4):465-70. PubMed ID: 3174609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]